Effect of liniment levamisole on cellular immune functions of patients with chronic hepatitis B

World Journal of Gastroenterology

Volumn 11, Issue 45, 2005, Pages 7208-7210

  Wang, Ke Xia ^a   Zhang, Li Hua ^a   Peng, Jiang Long ^a   Liang, Yong ^a   Wang, Xue Feng ^a   Zhi, Hui ^a   Wang, Xiang Xia ^b   Geng, Huan Xiong ^b  

^a ANHUI UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Huainan Railway Central Hospital   (China)

Author keywords

Cellular immune function; Chronic hepatitis B; Liniment levamisole; mIL 2R; T lymphocyte subsets

Indexed keywords

ASCORBIC ACID; BIOTIN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2 RECEPTOR; LEVAMISOLE; LIVER PROTECTIVE AGENT; SILYMARIN; STREPTAVIDIN; VITAMIN B GROUP;

ADULT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEPATITIS B; HUMAN; LINIMENT; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; T LYMPHOCYTE SUBPOPULATION;

EID: 31544432286     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i45.7208     Document Type: Article

References (26)

1. Wang KX, Peng JL, Wang XF, Tian Y, Wang J, Li CP. Detection of T lymphocyte subsets and mIL-2R on surface of PBMC in patients with hepatitis B. World J Gastroenterol 2003; 9: 2017-2020
2. Johnkoski JA, Peterson SM, Doerr RJ, Cohen SA. Levamisole regulates the proliferation of murine liver T cells through Kupffer-cell-derived cytokines. Cancer Immunol Immunother 1996; 43: 299-306
3. Daniluk J, Kandefer-Szerszen M. Isoprinosine and levamisole as stimulators of interferon production in blood leukocytes of patients with alcoholic liver cirrhosis. Arch Immunol Ther Exp (Warsz) 1997; 45: 183-187
4. Prakash MS, Rao VM, Reddy V. Effect of levamisole on the immune status of malnourished children. J Trop Pediatr 1998; 44: 165-166
5. Hajnzic TF, Kastelan M, Lukac J, Hajnzic T. Immunocompetent cells and lymphocyte reactivity to mitogens in levamisole-treated brain tumor children. Pediatr Hematol Oncol 1999; 16: 335-340
6. Martel F, Ribeiro L, Calhau C, Azevedo I. Inhibition by levamisole of the organic cation transporter rOCT1 in cultured rat hepatocytes. Pharmacol Res 1999; 40: 275-279
7. Artwohl M, Holzenbein T, Wagner L, Freudenthaler A, Waldhausl W, Baumgartner-Parzer SM. Levamisole induced apoptosis in cultured vascular endothelial cells. Br J Pharmacol 2000; 131: 1577-1583
8. Kayatas M. Levamisole treatment enhances protective antibody response to hepatitis B vaccination in hemodialysis patients. Artif Organs 2002; 26: 492-496
9. Cuesta A, Esteban MA, Meseguer J. Levamisole is a potent enhancer of gilthead seabream natural cytotoxic activity. Vet Immunol Immunopathol 2002; 89: 169-174
10. Bozic F, Bilic V, Valpotic I. Levamisole mucosal adjuvant activity for a live attenuated Escherichia coli oral vaccine in weaned pigs. J Vet Pharmacol Ther 2003; 26: 225-231
11. Kimball ES, Fisher MC. Levamisole effects on major histocompatibility complex and adhesion molecule expression and on myeloid cell adhesion to human colon tumor cell lines. J Natl Cancer Inst 1996; 88: 109-116
12. Sun A, Chia JS, Chang YF, Chiang CP. Levamisole and Chinese medicinal herbs can modulate the serum interleukin-6 level in patients with recurrent aphthous ulcerations. J Oral Pathol Med 2003; 32: 206-214
13. Holcombe RF, Milovanovic T, Stewart RM, Brodhag TM. Investigating the role of immunomodulation for colon cancer prevention: results of an in vivo dose escalation trial of levamisole with immunologic endpoints. Cancer Detect Prev 2001; 25: 183-191
14. Creagan ET, Rowland KM Jr, Suman VJ, Kardinal CG, Marschke RF Jr, Marks RS, Maples WJ. Phase II study of combined levamisole with recombinant interleukin-2 in patients with advanced malignant melanoma. Am J Clin Oncol 1997; 20: 490-492
15. Lai WH, Lu SY, Eng HL. Levamisole aids in treatment of refractory oral candidiasis in two patients with thymoma associated with myasthenia gravis: report of two cases. Chang Gung Med J 2002; 25: 606-611
16. Aksoy H, Baltaci S, Turkolmez K, Seckiner I, Beduk Y. Combined interferon alpha with levamisole in patients with metastatic renal cell carcinoma. Int Urol Nephrol 2001; 33: 457-459
17. Lam P, Yuen AP, Ho CM, Ho WK, Wei WI. Prospective randomized study of post-operative chemotherapy with levamisole and UFT for head and neck carcinoma. Eur J Surg Oncol 2001; 27: 750-753
18. Cafiero F, Gipponi M, Peressini A, Bertoglio S, Lionetto R. Preliminary analysis of a randomized clinical trial of adjuvant postoperative RT vs. postoperative RT plus 5-FU and levamisole in patients with TNM stage II-III resectable rectal cancer. J Surg Oncol 2000; 75: 80-88
19. Fu LS, Chi CS. Levamisole in steroid-sensitive nephrotic syndrome children with steroid-dependency and/or frequent relapses. Acta Paediatr Taiwan 2000; 41: 80-84
20. Sun A, Chia JS, Chang YF, Chiang CP. Serum interleukin-6 level is a useful marker in evaluating therapeutic effects of levamisole and Chinese medicinal herbs on patients with oral lichen planus. J Oral Pathol Med 2002; 31: 196-203
21. Donia AF, Amer GM, Ahmed HA, Gazareen SH, Moustafa FE, Shoeib AA, Ismail AM, Khamis S, Sobh MA. Levamisole: adjunctive therapy in steroid dependent minimal change nephrotic children. Pediatr Nephrol 2002; 17: 355-358
22. Sun A, Chiang CP. Levamisole and/or Chinese medicinal herbs can modulate the serum level of squamous cell carcinoma associated antigen in patients with erosive oral lichen planus. J Oral Pathol Med 2001; 30: 542-548
23. Wolmark N, Rockette H, Mamounas E, Jones J, Wieand S, Wickerham DL, Bear HD, Atkins JN, Dimitrov NV, Glass AG, Fisher ER, Fisher B. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999; 17: 3553-3559
24. Burch PA, Keppen MD, Schroeder G, Rubin J, Krook JE, Dalton RJ, Gerstner JB, Jancewicz MT, Ebbert LP. North Central Cancer Treatment Group Phase II study of 5-fluorouracil and high-dose levamisole for gastric and gastroesophageal cancer using survival as the primary endpoint of efficacy. Am J Clin Oncol 1999; 22: 505-508
25. Krastev Z, Jelev D, Antonov K, Alagozian V, Kotzev I. Chronic HBV infection. Immunomodulation with levamisole in viremic HBeAg positive or anti-HBe positive patients--a pilot study. Hepatogastroenterology 1999; 46: 3184-3188
26. Szeto C, Gillespie KM, Mathieson PW. Levamisole induces interleukin-18 and shifts type 1/type 2 cytokine balance. Immunology 2000; 100: 217-224